Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis

Cancer Research

Volumn 63, Issue 1, 2003, Pages 132-139

  Kumar Sinha, Chandan ^a   Ignatoski, Kathleen Woods ^a   Lippman, Marc E ^a   Ethier, Stephen P ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACTIVITY; FATTY ACID SYNTHESIS; GENE CONTROL; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0037226462     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kolibaba, K. S., and Druker, B. J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta, 1333: F217-F248, 1997.
2. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
3. Isola, J., Chu, L., DeVries, S., Matsumura, K., Chew, K., Ljung, B. M., and Waldman, F. M. Genetic alterations in ERBB2-amplified breast carcinomas. Clin. Cancer Res., 5: 4140-4145, 1999.
4. Albanell, J., Bellmunt, J., Molina, R., Garcia, M., Caragol, I., Bermejo, B., Ribas, A., Carulla, J., Gallego, O. S., Espanol, T., and Sole Calvo, L. A. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res., 16: 1027-1032, 1996.
5. Slamon, D. J. Proto-oncogenes and human cancers. N. Engl. J. Med., 317: 955-957, 1987.
6. Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., and Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res., 59: 1236-1243, 1999.
7. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
8. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 719-726, 2002.
9. Pegram, M. D., Pauletti, G., and Slamon, D. J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat., 52: 65-77, 1998.
10. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Wash. DC), 265: 1093-1095, 1994.
11. Slichenmyer, W. J., Elliott, W. L., and Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol., 28: 80-85, 2001.
12. Vincent, P. W., Patmore, S. J., Atkinson, B. E., Bridges, A. J., Kirkish, L. S., and Dudeck, R. Proc. Am. Assoc. Cancer Res., 39: 117, 1999.
13. Slichenmyer, W. J., and Fry, D. W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin. Oncol., 28: 67-79, 2001.
14. Ignatoski, K. M., Lapointe, A. J., Radany, E. H., and Ethier, S. P. erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology, 140: 3615-3622, 1999.
15. Ignatoski, K. M., Maehama, T., Markwart, S. M., Dixon, J. E., Livant, D. L., and Ethier, S. P. ERBB-2 overexpression confers P1 3′ kinase-dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer, 82: 666-674, 2000.
16. Alo, P. L., Visca, P., Marci, A., Mangoni, A., Botti, C., and Di Tondo, U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer (Phila.), 77: 474-482, 1996.
17. Epstein, J. I., Carmichael, M., and Partin, A. W. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology, 45: 81-86, 1995.
18. Gansler, T. S., Hardman, W., III, Hunt, D. A., Schaffel, S., and Hennigar, R. A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol., 28: 686-692, 1997.
19. Pizer, E. S., Lax, S. F., Kuhajda, F. P., Pasternack, G. R., and Kurman, R. J. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer (Phila.), 83: 528-537, 1998.
20. Swinnen, J. V., Vanderhoydonc, F., Elgamal, A. A., Eelen, M., Vercaeren, I., Joniau, S., Van Poppel, H., Baert, L., Goossens, K., Heyns, W., and Verhoeven, G. Selective activation of the fatty acid synthesis pathway in human prostate cancer, Int. J. Cancer, 88: 176-179, 2000.
21. Pizer, E. S., Chrest, F. J., DiGiuseppe, J. A., and Han, W. F. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res., 58: 4611-4615, 1998.
22. Pizer, E. S., Jackisch, C., Wood, F. D., Pasternack, G. R., Davidson, N. E., and Kuhajda, F. P. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res., 56: 2745-2747, 1996.
23. Kumar-Sinha, C., Varambally, S., Sreekumar, A., and Chinnaiyan, A. M. Molecular cross-talk between the TRAIL and interferon signaling pathways. J. Biol. Chem., 277: 575-585, 2002.
24. Church, G. M., and Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA, 81: 1991-1995, 1984.
25. Folch, J., Lees, M., and Stanley, G. H. S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem., 226: 497-509, 1956.
26. Swinnen, J. V., Ulrix, W., Heyns, W., and Verhoeven, G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl. Acad. Sci. USA, 94: 12975-12980, 1997.
27. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
28. Heemers, H., Maes, B., Foufelle, F., Heyns, W., Verhoeven, G., and Swinnen, J. V. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol., 15: 1817-1828, 2001.
29. American Cancer Society. Cancer Fact and Figures 2002. American Cancer Society, Atlanta, GA, 2002.
30. Arason, A., Barkardottir, R. B., and Egilsson, V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am. J. Hum. Genet., 52: 711-717, 1993.
31. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Wash. DC), 266: 66-71, 1994.
32. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G. Identification of the breast cancer susceptibility gene BRC42. Nature (Lond.). 378: 789-792, 1995.
33. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. Molecular portraits of human breast tumours. Nature (Lond.), 406: 747-752, 2000.
34. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., and Sondak, V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.), 406: 536-540, 2000.
35. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein Lonning, P., and Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98: 10869-10874, 2001.
36. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.), 415: 530-536, 2002.
37. Hedenfalk, I., Duggan, D. D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B. A., Esteller, M., Kallioniemi, O. P., Wilfond, B., Borg, A., and Trent, J. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med., 344: 539-548, 2001.
38. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet., 24: 227-235, 2000.
39. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res., 59: 803-806, 1999.
40. Chaib, H., Cockrell, E. K., Rubin, M. A., and Macoska, J. A. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia, 3: 43-52, 2001.
41. Fuller, G. N., Rhee, C. H., Hess, K. R., Caskey, L. S., Wang, R., Bruner, J. M., Yung, W. K., and Zhang, W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res., 59: 4228-4232, 1999.
42. Sallinen, P. K., Sallinen, S. L., Helen, P. T., Rantala, I. S., Rautiainen, E., Helin, H. J., Kalimo, H., and Haapasalo, H. K. Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol. Appl. Neurobiol., 26: 319-331, 2000.
43. Ram, T. G., Dilts, C. A., Dziubinski, M. L., Pierce, L. J., and Ethier, S. P. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Mol. Carcinog., 15: 227-238, 1996.
44. Ram, T. G., and Ethier, S. P. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ., 7: 551-561, 1996.
45. Ram, T. G., Hosick, H. L., and Ethier, S. P. Heregulin-β is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. J. Cell Physiol., 183: 301-313, 2000.
46. Fritz, G., Just, I., and Kaina, B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer, 81: 682-687, 1999.
47. Kos, J., and Lah, T. T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep., 5: 1349-1361, 1998.
48. Morino, M., Tsuzuki, T., Ishikawa, Y., Shirakami, T., Yoshimura, M., Kiyosuke, Y., Matsunaga, K., Yoshikumi, C., and Saijo, N. Specific regulation of HSPs in human tumor cell lines by flavonoids. In Vivo, 11: 265-270, 1997.
49. Inukai, T., Inoue, A., Kurosawa, H., Goi, K., Shinjyo, T., Ozawa, K., Mao, M., Inaba, T., and Look, A. T. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol. Cell, 4: 343-352, 1999.
50. Okubo, T., Truong, T. K., Yu, B., Itoh, T., Zhao, J., Grube, B., Zhou, D., and Chen, S. Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res., 61: 1338-1346, 2001.
51. Ungefroren, H., and Krull, N. B. Transcriptional regulation of the human biglycan gene. J. Biol. Chem., 271: 15787-15795, 1996.
52. Hunzelmann, N., Anders, S., Sollberg, S., Schonherr, E., and Krieg, T. Co-ordinate induction of collagen type 1 and biglycan expression in keloids. Br. J. Dermatol., 135: 394-399, 1996.
53. Stryer, L. Biochemistry, 3rd ed, New York: W. H. Freeman and Co., 1988.
54. Li, X. N., Gorospe, M., Chrest, F. I., Kumaravel, T. S., Evans, M. K., Han, W. F., and Pizer, E. S. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res., 61: 1493-1499, 2001.
55. Thupari, J. N., Pinn, M. L., and Kuhajda, F. P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun., 285: 217-223, 2001.
56. Pizer, E. S., Thupari, J., Han, W. F., Pinn, M. L., Chrest, F. J., Frehywot, G. L., Townsend, C. A., and Kuhajda, F. P. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res., 60: 213-218, 2000.
57. Swinnen, J. V., Roskams, T., Joniau, S., Van Poppel, H., Oyen, R., Baert, L., Heyns, W., and Verhoeven, G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer, 98: 19-22, 2002.
58. Milgraum, L. Z., Witters, L. A., Pasternack, G. R., and Kuhajda, F. P. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin. Cancer Res., 3: 2115-2120, 1997.
59. Swinnen, J. V., Heemers, H., Deboel, L., Foufelle, F., Heyns, W., and Verhoeven, G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene, 19: 5173-5181, 2000.
60. Brown, M. S., and Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 89: 331-340, 1997.
61. Kim, J. B., Sarraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B. B., and Spiegelman, B. M. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Investig., 101: 1-9, 1998.
62. Kotzka, J., Muller-Wieland, D., Roth, G., Kremer, L., Munck, M., Schurmann, S., Knebel, B., and Krone, W. Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade. J. Lipid Res., 41: 99-108, 2000.
63. Fleischmann, M., and Iynedjian, P. B. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem. J., 349: 13-17, 2000.
64. Yang, Y., Han, W., Morin, P., Chrest, F., and Pizer, E. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res., 279: 80-90, 2002.